LLY vs. TMUS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at LLY and TMUS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | LLY | TMUS |
|---|---|---|
| Company Name | Eli Lilly and Company | T-Mobile US, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Communication Services |
| GICS Industry | Pharmaceuticals | Wireless Telecommunication Services |
| Market Capitalization | 623.33 billion USD | 283.31 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | June 1, 1972 | April 19, 2007 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of LLY and TMUS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | LLY | TMUS |
|---|---|---|
| 5-Day Price Return | -1.12% | -2.51% |
| 13-Week Price Return | -2.78% | 4.53% |
| 26-Week Price Return | -19.81% | -4.41% |
| 52-Week Price Return | -27.13% | 28.15% |
| Month-to-Date Return | -6.05% | 5.59% |
| Year-to-Date Return | -9.93% | 14.05% |
| 10-Day Avg. Volume | 5.47M | 3.71M |
| 3-Month Avg. Volume | 4.51M | 4.42M |
| 3-Month Volatility | 40.35% | 23.82% |
| Beta | 0.45 | 0.61 |
Profitability
Return on Equity (TTM)
LLY
88.36%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
TMUS
19.69%
Wireless Telecommunication Services Industry
- Max
- 27.67%
- Q3
- 18.94%
- Median
- 13.35%
- Q1
- 6.38%
- Min
- -8.07%
In the upper quartile for the Wireless Telecommunication Services industry, TMUS’s Return on Equity of 19.69% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
LLY
25.91%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
TMUS
14.53%
Wireless Telecommunication Services Industry
- Max
- 17.18%
- Q3
- 13.67%
- Median
- 9.33%
- Q1
- 4.43%
- Min
- -5.10%
A Net Profit Margin of 14.53% places TMUS in the upper quartile for the Wireless Telecommunication Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
LLY
32.37%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
TMUS
23.08%
Wireless Telecommunication Services Industry
- Max
- 29.85%
- Q3
- 23.51%
- Median
- 20.46%
- Q1
- 16.06%
- Min
- 9.07%
TMUS’s Operating Profit Margin of 23.08% is around the midpoint for the Wireless Telecommunication Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | LLY | TMUS |
|---|---|---|
| Return on Equity (TTM) | 88.36% | 19.69% |
| Return on Assets (TTM) | 16.02% | 5.78% |
| Net Profit Margin (TTM) | 25.91% | 14.53% |
| Operating Profit Margin (TTM) | 32.37% | 23.08% |
| Gross Profit Margin (TTM) | 82.64% | 63.61% |
Financial Strength
Current Ratio (MRQ)
LLY
1.28
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
TMUS
1.21
Wireless Telecommunication Services Industry
- Max
- 1.26
- Q3
- 1.00
- Median
- 0.71
- Q1
- 0.60
- Min
- 0.36
TMUS’s Current Ratio of 1.21 is in the upper quartile for the Wireless Telecommunication Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
LLY
2.18
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
TMUS
1.45
Wireless Telecommunication Services Industry
- Max
- 2.92
- Q3
- 2.15
- Median
- 1.57
- Q1
- 0.91
- Min
- 0.44
TMUS’s Debt-to-Equity Ratio of 1.45 is typical for the Wireless Telecommunication Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
TMUS
5.31
Wireless Telecommunication Services Industry
- Max
- 12.67
- Q3
- 6.16
- Median
- 3.95
- Q1
- 1.81
- Min
- -1.20
TMUS’s Interest Coverage Ratio of 5.31 is positioned comfortably within the norm for the Wireless Telecommunication Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | LLY | TMUS |
|---|---|---|
| Current Ratio (MRQ) | 1.28 | 1.21 |
| Quick Ratio (MRQ) | 0.53 | 1.08 |
| Debt-to-Equity Ratio (MRQ) | 2.18 | 1.45 |
| Interest Coverage Ratio (TTM) | 20.36 | 5.31 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
LLY
0.77%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
LLY’s Dividend Yield of 0.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
TMUS
1.29%
Wireless Telecommunication Services Industry
- Max
- 7.63%
- Q3
- 5.13%
- Median
- 3.22%
- Q1
- 2.33%
- Min
- 0.00%
TMUS’s Dividend Yield of 1.29% is in the lower quartile for the Wireless Telecommunication Services industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
LLY
36.46%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
TMUS
30.87%
Wireless Telecommunication Services Industry
- Max
- 145.86%
- Q3
- 109.87%
- Median
- 78.85%
- Q1
- 48.65%
- Min
- 0.00%
TMUS’s Dividend Payout Ratio of 30.87% is in the lower quartile for the Wireless Telecommunication Services industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.
Dividend at a Glance
| Symbol | LLY | TMUS |
|---|---|---|
| Dividend Yield (TTM) | 0.77% | 1.29% |
| Dividend Payout Ratio (TTM) | 36.46% | 30.87% |
Valuation
Price-to-Earnings Ratio (TTM)
LLY
47.48
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 47.48, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
TMUS
23.93
Wireless Telecommunication Services Industry
- Max
- 34.45
- Q3
- 23.52
- Median
- 16.68
- Q1
- 13.97
- Min
- 7.48
A P/E Ratio of 23.93 places TMUS in the upper quartile for the Wireless Telecommunication Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
LLY
12.30
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 12.30, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
TMUS
3.48
Wireless Telecommunication Services Industry
- Max
- 2.56
- Q3
- 1.94
- Median
- 1.37
- Q1
- 1.22
- Min
- 0.62
With a P/S Ratio of 3.48, TMUS trades at a valuation that eclipses even the highest in the Wireless Telecommunication Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
LLY
40.43
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
TMUS
4.43
Wireless Telecommunication Services Industry
- Max
- 4.87
- Q3
- 2.93
- Median
- 2.02
- Q1
- 1.33
- Min
- 0.40
TMUS’s P/B Ratio of 4.43 is in the upper tier for the Wireless Telecommunication Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | LLY | TMUS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 47.48 | 23.93 |
| Price-to-Sales Ratio (TTM) | 12.30 | 3.48 |
| Price-to-Book Ratio (MRQ) | 40.43 | 4.43 |
| Price-to-Free Cash Flow Ratio (TTM) | 326.03 | 23.69 |